CureVac COVID-19 vaccine recorded 48% efficacy in final study read



CureVac said the COVID-19 vaccine was 48% effective in the final analysis of an important population trial, slightly better than the 47% reported after the first read two weeks ago.

German biotechnology companies show that efficacy measured by prevention of symptomatic disease is slightly better, at 53%, excluding study participants over the age group of 60, which is the most severely affected age group. Said that.

CureVac announced on June 16 that the COVID-19 vaccine, known as CVnCoV, showed 47% effectiveness in reading the first test, new variants showed headwinds, and investor confidence in their ability to take rival shots. Said it lowered.

It has wiped out billions of euros from its market value.

The news on Wednesday dropped 10.2 percent of the company’s US-listed stock to $ 66 after the bell.

Late trials of BioNTech / Pfizer and Moderna vaccines, which are based on mRNA technology such as CureVac, showed efficacy rates well over 90% in all age groups, but the original version of coronavirus prevailed. It was done at that time.

However, data on their products have so far suggested that protection against new variants is somewhat weaker.

A CureVac study of approximately 40,000 adult volunteers in Europe and Latin America found that it was effective in the age group <60 years when only moderate to severe symptoms were considered and mild cases were excluded. Shown to be%.

CureVac said it sent the data to the European Medicines Agency (EMA) as part of an ongoing dialogue with EU drug regulators.

CureVac previously stated that the regulatory hurdle is, in principle, 50% effective, but various other considerations may be relevant.

“In this final analysis, CVnCoV shows strong public health value by completely protecting study participants aged 18-60 years from hospitalization and death, and 77% from moderate to severe illness. This is an effectiveness profile and we consider it important. Contributions to help manage the pandemic and dynamic variants of COVID-19, “said CEO Franz Warner.・ Haas says.

CureVac recorded a total of 228 infections in the final analysis after recording 134 cases in the interim analysis.

Public health officials around the world are driving the rapid deployment of available vaccines to combat more contagious mutations in COVID-19, such as the delta variant that first appeared in India.

The EMA states that it does not impose a 50% efficacy threshold on vaccines and that complete study data is needed to properly assess the benefits and risks of shots.

Under CureVac’s only major supply contract for the products tested in the trial, the European Union secured up to 405 million vaccines in November, of which 180 million are optional.

Betting on CureVac’s technology, the UK ordered in February 50 million conditional doses of an undeveloped vaccine based on a product tested in a trial.

CureVac has built a network of manufacturing partners such as the Swiss Celonic Group, Novartis, Bayer, Fareva, Wacker and Rentschler Biopharma SE.

Posted on